Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 360

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 360
---
 72 |

F-21

LB Pharmaceuticals Inc Notes to Financial Statements Short-term lease expense includes expenses related to the Company’s 2018 operating lease agreement for office space in New York, New York. The lease agreement was month-to-monthand could be terminated by either party with three months’ written notice. The Company terminated the lease effective September 30, 2024. The Company made the policy election to exclude short-term leases from recognition and measurement under ASC 842. The Company made an advance payment of $0.06 million for the first month of rent on the lease liabilities during the year ended December 31, 2024. Supplemental balance sheet information related to operating leases as of December 31, 2024 and 2023 was as follows (in thousands):

|                                                  |     | December 31, 
 2024         |       |   |     | December 31, 
 2023         |   |   |
|:-------------------------------------------------|:----|:-------------|------:|:--|:----|:-------------|:--|:--|
| Operating lease                                  
 right-of-use assets                              |     | $            | 2,298 |   |     | $            | — |   |
| Operating lease liability, current               |     |              |   487 |   |     |              | — |   |
| Operating lease liability, noncurrent            |     |              | 3,216 |   |     |              | — |   |
| Total operating lease liability                  |     | $            | 3,703 |   |     | $            | — |   |
| Weighted average remaining lease term (in years) |     |              |   7.3 |   |     |              | — |   |
| Weighted average discount rate                   |     |              |   9.6 | % |     |              | — | % |

As of December 31, 2024, future minimum commitments under operating leases were as follows:

| Year ended December 31, 2025    |     | As of December 31, 2024 |    487 |   |
|:--------------------------------|:----|:------------------------|-------:|:--|
| Year ended December 31, 2026    |     |                         |    730 |   |
| Year ended December 31, 2027    |     |                         |    730 |   |
| Year ended December